| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Product Type | |
| Promoter | |
| Reporter | |
| Selection Marker | Blasticidin, N/A, Puromycin |
| Shipping | |
| Species |
Background
CD274 encodes PD-L1 (programmed cell death 1 ligand 1, also known as B7-H1), a transmembrane immune checkpoint ligand. By binding the inhibitory receptor PD-1 on T cells, PD-L1 dampens T cell receptor signaling, promoting peripheral tolerance and limiting immune-mediated tissue damage. Many tumors upregulate PD-L1 to suppress anti-tumor T cell responses and evade immune clearance. The PD-1/PD-L1 axis is a central target of cancer immunotherapy, and checkpoint-blockade antibodies against this pathway are widely used clinically, making CD274 a key focus of immuno-oncology research.
Product Description & Applications
The PD-L1 (B7-H1) ORF cDNA Lentivirus delivers the PD-L1 (CD274) open reading frame for stable overexpression in mammalian cells. Expression of the ORF, fused to a C-terminal V5 tag, is driven by a CMV or EF1α promoter, with a GFP or RFP reporter and optional blasticidin or puromycin selection marker separated by self-cleaving peptide sequences for independent translation. The lentiviral vectors are optimized for high expression and reliable genome integration; ORF accuracy is confirmed by sequencing and protein expression validated by transient transfection.
Supplied as high-titer, third-generation, VSV-G-pseudotyped particles, it efficiently transduces primary and thawed cells, supporting stable PD-L1-expressing cell lines for studying immune checkpoint signaling and immunotherapy.
About This Product
This ORF cDNA lentivirus enables stable overexpression of CD274 (NCBI Accession: NM_014143, NM_021893) in mammalian cells via a third-generation, VSV-G pseudotyped delivery system. The ORF cDNA is fused to a C-terminal epitope tag (V5, Myc, or HA) and expressed under a strong constitutive promoter (CMV). Reporter and selection marker components (GFP, RFP; Blasticidin, Puromycin) are co-expressed via self-cleaving P2A peptides, enabling independent protein production without fusion-tag artifacts.
Ultra-purification by PEG precipitation and sucrose gradient centrifugation yields high-titer particles suitable for primary cells, suspension cultures, and stem cells. Stable polyclonal cell lines are established within 10–14 days by antibiotic selection or FACS sorting. For in vivo applications, the serum-free formulation and VSV-G envelope support direct administration or further concentration for stereotactic injection.
Can't find the lentiviral construct you need, or want to adjust key design elements? Contact us to discuss custom LV design and optional add-ons.
Common customization requests
- Insert / payload: replace the gene/sequence, swap to a different isoform, add mutations, or optimize cloning features.
- Expression design: change promoter (e.g., CMV/EF1α/PGK), add enhancers, or adjust regulatory elements.
- Reporters: add/swap GFP/RFP/mCherry/luciferase (single or dual reporters where applicable).
- Selection markers: add/swap puromycin/blasticidin/neomycin or fluorescent selection options.
- Vector format: switch between OE, shRNA, CRISPR (sgRNA/Cas systems), or control vectors (where supported).
Add-ons you can request
- Control viruses: empty vector, non-targeting shRNA, reporter-only controls, or matched backbone controls.
- Packaging / format: concentration options, aliquoting, or custom fill volume for screening workflows.
- Documentation: construct map/sequence confirmation package (as available) and batch documentation.
What to include in your request
- Target cell type/model (cell line or primary cells) and intended readout (reporter, knockdown, OE, etc.)
- Insert sequence (FASTA) or reference ID, plus any required tags/mutations
- Promoter, reporter, and selection marker preferences
- Desired scale and preferred format (aliquots / concentration requests)
Email us at support@biohippo.com or use the Talk to a Scientist request form.
